TriangleNCT01222286 · REGISTRY CONDITION SEARCH
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2026-05-14
The purpose of this study is to evaluate the anti-tumor activity, safety and pharmacology of two dose regimens (0.2 and 2 mg/kg)of IPH2101 in patients with Smoldering Multiple Myeloma.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: 1. SMM of any risk level according to a definition derived of the International Myeloma Working Group definition ( Br J Haematol 2003; 121: 749) : Serum M protein ≥ 3 g/dl , AND/OR Bone Marrow plasma cells ≥ 10 % with no evidence of end-organ damage (CRAB) * (C)Absence of hypercalcemia : Ca \< 10.5 mg/dl * (R)Absence of renal failure : creatinine \< 2mg/dl (177 μmol/l) or calculated creatinine clearance(according to MDRD) \> 50 ml/min * (A)Absence of anemia : Hb \> 11 g/dl * (B)Absence of lytic bone lesion on standard skeletal survey (MRI could be used if clinically indicated) 2. Measurable disease defined as a disease with a serum M protein ≥ 1 g/dl 3. No evidence of fatigue, recurrent infections or any clinical suspicion of MM 4. Diagnosis of SMM confirmed on two consecutive assessments (ie fluctuation under 25% of serum protein level) performed with at least a 4 week interval. 5. Age \> 18 years or \< 75 years 6. ECOG performance status of 0 or 1 7. Male or female patient who accepts and is able to use recognised effective contraception (oral contraceptives, IUCD, barrier method of contraception in conjunction with spermicidal jelly) throughout the study when relevant 8. Informed consent signed by the patient Exclusion Criteria: 1. Previous treatment having a proven or potential impact on myelomatous cells proliferation or survival (including IMiDs or proteasome inhibitors, conventional chemotherapies within the last 5 years, steroids within the last month prior to enrolment). Previous bisphosphonates started less than 3 months prior to enrolment. 2. Use of any investigational agent within the last 3 months 3. Clinical laboratory values at screening * Platelet \< 75 x 10\^9 /l * ANC \< 1.5 x 10\^9 /l * Bilirubin levels \>1.5 ULN ; ALT and AST \> 3 ULN (grade 1 NCI) 4. Primary or associated amyloidosis 5. Abnormal cardiac status with any of the following 1. NYHA stage III or IV congestive heart failure 2. myocardial infarction within the previous 6 months 3. symptomatic cardiac arrhythmia requiring treatment or persisting despite appropriate treatment 6. Current active infectious disease or positive serology for HIV, HCV or positive Hbs Antigen 7. History of or current auto-immune disease 8. History of other active malignancy within the past five years (apart from basal cell carcinoma of the skin, or in situ cervix carcinoma). 9. Serious concurrent uncontrolled medical disorder 10. History of allograft or solid organ transplantation 11. Pregnant or lactating women 12. Any condition potentially hampering compliance with the study protocol and follow-up schedule
- healthy Volunteers
- false
- maximum Age
- 80 Years
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- 0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
- intervention Names
- Drug: IPH2101
- label
- IPH2101 0.2 mg/kg
- type
- EXPERIMENTAL
- description
- 2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
- intervention Names
- Drug: IPH2101
- label
- IPH2101 2 mg/kg
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- IPH2101 0.2 mg/kg
- IPH2101 2 mg/kg
- description
- 0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
- name
- IPH2101
- other Names
- a human monoclonal anti-KIR antibody (1-7F9)
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 30
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- The primary end point is the rate of patients achieving an objective response (defined according to the International Myeloma Working Group uniform response criteria), including minimal response, (as derived from the European Society for Blood and Marrow Transplantation criteria), achieved at any time until end of study and confirmed on two consecutive assessments at 4 weeks interval.
- measure
- Rate of Patients Achieving an Objective Response
- time Frame
- from start to end of study (14 months)
- secondary Outcomes
- description
- adverse events, physical examination and biological changes during the whole clinical trial.
- measure
- Safety Assessment
- time Frame
- Adverse events collected from screening visit (date of signature of Inform Consent Form) up to the End of Study, up to 14 months
- description
- biological activity of IPH2101 on KIR occupancy at End of Treatment
- measure
- Pharmacodynamics of IPH2101
- time Frame
- from start to end of study (14 months)
- description
- * any change of M-protein in serum occurring during the study (\>25 percentage increase in level of serum M-protein) * progression to active Multiple Myeloma Definition of active Multiple Myeloma: Evidence of progression based on the IMWG criteria for progressive disease in myeloma and any one or more of the following felt related to the underlying clonal plasma cell proliferative disorder : * Development of new soft tissue plasmacytomas or bone lesions * Hypercalcemia (\> 11mg/100ml) * Decrease in hemoglobin of \> 2g/100ml * Rise in serum creatinine by 2 mg/100ml or more
- measure
- Secondary Anti-tumor Activity
- time Frame
- from start to end of study (14 months)
Full study description
- brief Summary
- The purpose of this study is to evaluate the anti-tumor activity, safety and pharmacology of two dose regimens (0.2 and 2 mg/kg)of IPH2101 in patients with Smoldering Multiple Myeloma.
- detailed Description
- This is a randomized Phase II, open label, multi-centre study, with two independent arms. Patients receive 6 injections of IPH2101, at the dose of 0.2 mg/kg or 2 mg/kg (according to their randomization) administered over one hour infusion at four weeks intervals. A patient whose disease achieves at least a minimal response to study treatment at any time during the initial period of 6 cycles can be treated with an additional period of treatment of 6 cycles. Patients are followed 6 months after treatment completion or until a KIR occupancy level \< 30% (i.e if the time required for KIR desaturation was \> 6 months), whichever is longer.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-84ae759a3b77b17e65e4
- requested nct id
- NCT01222286
- primary nct id
- NCT01222286
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- payload sha256
- d241bb270ee3b1db37246ba5376efb806b2548a1ae1ebf2dbb032f1533700577
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-84ae759a3b77b17e65e4
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT01222286
- occurrences
- context exact
- NCT01222286
- end
- 11
- exact text
- NCT01222286
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Plasma Cell Neoplasms
- query disease state id
- ds-plasma-cell-neoplasms
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- source json pointer
- /studies/31/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 7ce7ca838d1ad5c48e887916a74a366bfbd5fdff0ac7f994d37efb9e264b5335
Preserved source evidence · Not medical advice